[DOI] [Google Scholar] 11.Powell-Wiley T.M., Poirier P., Burke L.E., Desprs J.-P., Gordon-Larsen P., Lavie C.J., Lear S.A., Ndumele C.E., Neeland I.J., Sanders P., et al
Individuals with methylation issues, such as those with MTHFR variants, might respond differently to NNMT inhibition
The lack of independent replication or detailed data means these findings, while encouraging, are not considered high-quality evidence by todays standards
Always let us know if you experience any unexpected side effects
Clinic-grade TB-500 from a licensed 503A compounding pharmacy carries a significantly lower risk profile than unregulated sources
Given that ErbB contributes to IGF-IR/InsR and ER antagonist resistance, co-targeting ErbB, IGF-IR/InsR, and ER may achieve maximal anti-cancer effect on ER+ breast cancer [110]